Previous 10 | Next 10 |
2024-04-23 15:00:03 ET Wan Nurhayati from CFRA issued a price target of $108.00 for NVS on 2024-04-23 13:11:00. The adjusted price target was set to $108.00. At the time of the announcement, NVS was trading at $97.27. NVS currently trades -10.58% versus its 52 week high ...
2024-04-23 14:08:57 ET More on Novartis Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis AG 2024 Q1 - Results - Earnings Call Presentation Biggest stock movers today: SPOT...
2024-04-23 13:32:13 ET More on Sanofi Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript) Sanofi succeeds in late-stage trial for ...
2024-04-23 11:55:26 ET Novartis AG (NVS) Q1 2024 Earnings Conference Call April 23, 2024, 08:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference ...
2024-04-23 11:15:11 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q1 2024 Earnings Call Apr 23, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
2024-04-23 10:00:00 ET Summary Novartis reported strong first quarter results with an EPS beat and revenue beat. The company's core growth products, including Entresto, Cosentyx, Kesimpta, Kisqali and Leqvio, drove the strong first-quarter performance. Novartis increased its f...
Kiniksa Pharmaceuticals Ltd. (KNSA) is expected to report $-0.14 for Q1 2024 Agree Realty Corporation (ADC) is expected to report $1.01 for Q1 2024 1st Colonial Bancorp Inc (FCOB) is expected to report for Q1 2024 Equity Residential of Beneficial Interest (EQR) is expected to report $...
2024-04-23 05:15:48 ET More on related stocks: Novartis Looks To Get Back On Track With Q1 Earnings Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation Nucor: A Solid Start To 2024 Novartis beats top-line and bottom-line...
2024-04-23 01:27:04 ET More on Novartis Novartis Looks To Get Back On Track With Q1 Earnings Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation Novartis: Higher Guidance, Now A Buy FDA requires labeling changes to CAR-T...
2024-04-22 11:42:42 ET More on Novartis Novartis Looks To Get Back On Track With Q1 Earnings Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation Novartis: Higher Guidance, Now A Buy FDA requires labeling changes to CAR-T...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...